Evidence map›Paper›PMID 30551737›Full record

ArticleJournal of translational medicine2018

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Zahi I Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M Keck, Max Morris, Alexander R Guimaraes, Brooke R Beckett, Uma Borate, Charles D Lopez and 7 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Precision oncology for breast cancer through clinical trials.Clinical & experimental metastasis · 2022
    Review
  14. Functional impact and targetability ofCold Spring Harbor molecular case studies · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Zahi I MitriOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.ORCID 0000-0001-8765-7723
Swapnil ParmarOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Brett JohnsonOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Annette KolodzieOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Jamie M KeckOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Max MorrisOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Alexander R GuimaraesOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Brooke R BeckettOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Uma BorateOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Charles D LopezOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Kathleen A KemmerOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Joshi J AlumkalOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Tomasz M BeerOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Christopher L CorlessOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Gordon B MillsOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Joe W GrayOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Raymond C BerganOregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA. bergan@ohsu.edu.
Oregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was implemented. This report describes our findings to date, including the frequency with which mutational testing led to precision-guided therapy and outcome for those patients.

methodsEligible patients presenting to Oregon Health and Science University Knight Cancer Institute were enrolled on the study. Patients with biopsy proven metastatic or locally advanced unresectable prostate cancer, breast cancer, pancreatic adenocarcinoma, or refractory acute myelogenous leukemia receiving standard of care therapy were eligible. Metastatic site biopsies were collected and analyzed using the Knight Diagnostic Lab GeneTrails comprehensive solid tumor panel (124 genes). CLIA certified genomic information was made available to the treating physician.

resultsBetween 1/26/2017 and 5/30/2018, 38 patients were enrolled, with 28 successfully undergoing biopsy. Of these, 25 samples yielded sufficient tumor for analysis. The median biopsy cellularity and number of cores collected were 70% (15-90%) and 5 (2-20), respectively. No procedure-related complications occurred. GeneTrails analysis revealed that 22 of 25 (88%) tumor samples harbored at least one potentially actionable mutation, and 18 (72%) samples harbored 2 or more potentially actionable mutations. The most common genetic alterations identified involved: DNA damage repair genes, cell cycle regulating genes, PIK3CA/Akt/mTOR pathway, and FGF gene family. To date, CLIA certified genomic results were used by treating physicians for precision-guided therapy in 5 (23%) patients.

conclusionWe report the feasibility of real-time tissue acquisition and analysis to support a successful translational oncology platform. The workflow will provide the foundation to improve access and accrual to biomarker driven precision oncology trials.

Indexed as

Medical OncologyMolecular Targeted TherapyTranslational Research, BiomedicalAdultAgedAged, 80 and overBreast NeoplasmsCohort StudiesFatal OutcomeFemaleHumansMaleMiddle AgedMutation RateBiomarkersClinical trialsPrecision oncologyTargeted therapyTranslational research

Identifiers

PMID30551737
PMCPMC6295039
OpenAlexW2904265289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.